Prostate Cancer - Results from #1140

Toward Informed Selection and Interpretation of Clinical Genomic Tests in Prostate Cancer. April 1, 2024

Magnetic Resonance Imaging, Clinical, and Biopsy Findings in Suspected Prostate Cancer: A Systematic Review and Meta-Analysis. April 1, 2024

The association of patient and disease characteristics with the overtreatment of low-risk prostate cancer from 2010 to 2016. April 1, 2024

Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer. April 1, 2024

Tumor upgrading among very favorable intermediate-risk prostate cancer patients treated with robot-assisted radical prostatectomy: how can it impact the clinical course? April 1, 2024

Military service and health-related quality of life among gay and bisexual prostate cancer survivors: Results from the Restore -2 study. March 31, 2024

Quantification and molecular correlates of tertiary lymphoid structures in primary prostate cancer. March 29, 2024

The Current Therapeutic Landscape for Metastatic Prostate Cancer. March 29, 2024

Exploring Information Seeking Anxiety Among Localized Prostate Cancer Patients. March 29, 2024

Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancer. March 29, 2024

Racial differences in postpandemic trends in prostate-specific antigen screening. March 29, 2024

Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate Cancer. March 28, 2024

A practical guide for assessing and managing cardiovascular risk during androgen-deprivation therapy in patients with prostate cancer. March 28, 2024

Interaction of patient age and high-grade prostate cancer on targeted biopsies of MRI suspicious lesions. March 28, 2024

Patterns of B-cell lymphocyte expression changes in pre- and post-malignant prostate tissue are associated with prostate cancer progression. March 28, 2024

Real-world prostate-specific antigen reduction and survival outcomes of metastatic hormone-sensitive prostate cancer patients treated with apalutamide: An observational, retrospective, and multicentre study. March 28, 2024

Clinically-observed FOXA1 mutations upregulate SEMA3C through transcriptional derepression in prostate cancer. March 27, 2024

Case report: Exceptional and durable response to Radium-223 and suspension of androgen deprivation therapy in a metastatic castration-resistant prostate cancer patient. March 27, 2024

A Signal-finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer: Results from CYCLONE 1. March 27, 2024

Real-World Evaluation of Primary Versus Secondary Prevention of Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer. March 27, 2024

Page 58 of 1436